Sign in →

Test Code CAVP California Virus (La Crosse) IgG and IgM, Serum

Useful For

Aiding the diagnosis of California (La Crosse) encephalitis using serum specimens

Method Name

Immunofluorescence Assay (IFA)

Reporting Name

Calif Virus (LaCrosse)IgG and IgM,S

Specimen Type

Serum


Ordering Guidance


This assay detects only California virus. For a complete arbovirus panel, order ARBOP / Arbovirus Antibody Panel, IgG and IgM, Serum.



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into plastic vial.


Specimen Minimum Volume

0.15 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject

Clinical Information

California (La Crosse) virus is a member of the Bunyaviridae family and is one of the arthropod-borne encephalitides. It is transmitted by various Aedes and Culex mosquitoes and is found in such intermediate hosts as rabbits, squirrels, chipmunks, and field mice.

 

California meningoencephalitis is usually mild and occurs in late summer. Ninety percent of infections are seen in children and adolescents younger than 15 years, usually from rural areas. The incubation period is estimated to be 7 days, and acute illness lasts 10 days or less in most instances. Typically, the first symptoms are nonspecific, lasting 1 to 3 days, and are followed by the appearance of central nervous system signs and symptoms, such as stiff neck, lethargy, and seizures, which usually abate within 1 week. Symptomatic infection is almost never recognized in those older than 18 years. The most important sequela of California virus encephalitis is epilepsy, which occurs in about 10% of children; almost always in patients who have had seizures during the acute illness. A few patients (estimated 2%) have persistent paresis. Learning disabilities or other objective cognitive deficits have been reported in a small proportion (no more than 2%) of patients. Learning performance and behavior of most recovered patients are not distinguishable from comparison groups in these same areas.

 

Infections with arboviruses can occur at any age. The age distribution depends on the degree of exposure to the specific transmitting arthropod relating to age, sex, and occupational, vocational, and recreational habits of the individuals. Once humans have been infected, the severity of the host response may be influenced by age. Serious California (La Crosse) virus infections primarily involve children, especially boys. Men exposed to California viruses have high prevalence rates of antibody but usually show no serious illness. Infection among men is primarily due to working conditions and sports activities taking place where the vector is present.

Reference Values

IgG: <1:10

IgM: <1:10

Reference values apply to all ages.

Interpretation

In patients infected with these or related viruses, IgG antibody is generally detectable within 1 to 3 weeks of onset, peaking within 1 to 2 months and declining slowly thereafter.

 

IgM class antibody is also reliably detected within 1 to 3 weeks of onset, peaking and rapidly declining within 3 months.

 

Single serum specimen IgG of 1:10 or greater indicates exposure to the virus.

 

Results from a single serum specimen can differentiate early (acute) infection from past infection with immunity if IgM is positive (suggests acute infection).

 

A 4-fold or greater rise in IgG antibody titer in acute and convalescent sera indicates recent infection.

Cautions

All results must be correlated with clinical history and other data available to the attending physician.

 

Specimens collected within the first 2 weeks after onset are variably negative for IgG antibody and should not be used to exclude the diagnosis of arboviral disease. If arboviral infection is suspected, a second specimen should be collected and tested 10 to 21 days later.

 

Usually, when an infection with an arbovirus is suspected, it is too late to isolate the virus or collect serum specimens to detect a rise of antibody titer.

Method Description

The indirect immunofluorescent antibody (IFA) assay is a 2-stage "sandwich" procedure. In the first stage, the patient serum is diluted in Pretreatment Diluent for IgM and phosphate buffered saline (PBS) for IgG, added to appropriate slide wells in contact with the substrate, and incubated. Following incubation, the slide is washed in PBS which removes unbound serum antibodies. In the second stage, each antigen well is overlaid with fluorescein-labeled antibody to IgM and IgG. The slide is incubated allowing antigen-antibody complexes to react with the fluorescein-labeled anti-IgM and anti-IgG. After the slide is washed, dried, and mounted, it is examined using fluorescence microscopy. Positive reactions appear as cells exhibiting bright apple-green cytoplasmic fluorescence against a background of red negative control cells. Semi-quantitative endpoint titers are obtained by testing serial dilutions of positive specimens.(Package inserts: Arbovirus IFA IgM and Arbovirus IFA IgG Instructions for Use. Focus Diagnostics; Rev. 03, 02/17/2023)

Day(s) Performed

Monday through Friday

Report Available

Same day/1 to 4 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86651 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CAVP Calif Virus (LaCrosse)IgG and IgM,S 96499-9

 

Result ID Test Result Name Result LOINC Value
8764 Calif (LaCrosse) Encep Ab, IgG, S In Process
87280 Calif (LaCrosse) Encep Ab, IgM, S In Process

Testing Algorithm

For more information see Mosquito-borne Disease Laboratory Testing.